{"id":409459,"date":"2021-01-06T08:33:18","date_gmt":"2021-01-06T13:33:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=409459"},"modified":"2021-01-06T08:33:18","modified_gmt":"2021-01-06T13:33:18","slug":"chemocentryx-to-participate-in-two-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/","title":{"rendered":"ChemoCentryx to Participate in Two Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MOUNTAIN VIEW, Calif., Jan.  06, 2021  (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.:<\/p>\n<ul>\n<li>\n          <strong>39th Annual J.P. Morgan Healthcare Conference<\/strong><br \/>\n          <br \/>Wednesday, January 13 at 11:40 a.m. Eastern Time<\/p>\n<\/li>\n<li>\n          <strong>H.C. Wainwright Virtual BioConnect Conference<\/strong><br \/>\n          <br \/>On-demand presentation available beginning Monday, January 11 at\u00a06:00 a.m.\u00a0Eastern Time<\/li>\n<\/ul>\n<ul>\n<li>\n          <strong>Clinical <\/strong><br \/>\n          <strong>Trial<\/strong><br \/>\n          <strong> Panel <\/strong><br \/>\n          <strong>Discussion <\/strong><br \/>\n          <strong>at the H.C. Wainwright Virtual BioConnect Conference<br \/><\/strong>Monday, January 11 at\u00a012:00 p.m.\u00a0Eastern Time<\/li>\n<\/ul>\n<p>Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company&#8217;s website at www.ChemoCentryx.com. Replays of both the J.P. Morgan and H.C. Wainwright presentations will be available on the Company&#8217;s website for two weeks following the respective presentation dates.<\/p>\n<p>\n        <strong>About\u00a0ChemoCentryx<\/strong>\n      <\/p>\n<p>ChemoCentryx\u00a0is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer.\u00a0ChemoCentryx\u00a0targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx\u2019s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the\u00a0U.S. Food and Drug Administration, along with a Marketing Authorization Application by the\u00a0European Medicines Agency. Avacopan is also in late-stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).<\/p>\n<p>ChemoCentryx\u00a0also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p align=\"justify\">Susan M. Kanaya<br \/>Executive Vice President,<br \/>Chief Financial and Administrative Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EHXumQNaMVLthDUVQG8XPlt1HvnB1juI1BlIXZse6pIcUlabFG80YwC663AXgSH1AtIiASP0F52zrKZcpMG-6wmEWgSfZVXXMDnddBJ18v4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investor@chemocentryx.com<\/a><\/p>\n<p>Media: <br \/>Stephanie Tomei<br \/>408.234.1279<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NeeRRnp6vlnzOwV_DmDAEF87BNBkuWtmmrZqacgNkMAyHppTPCrNHlphR03Iwowv2JF3Dpv2G-7l3gv6kxEwMNv6CmPHfuVHGE26sYaBX3A=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">media@chemocentryx.com<\/a><\/p>\n<p>Investors:<br \/>Lee Roth, Burns McClellan<br \/>212.213.0006 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hOyLUij0gUN3PTV4fUtl2HFZiaqUvDY7pQXN_1EMpZoATEv8YUymHGPZ_halGi7CwxF3VRC4n7OflyZn8WUeeg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">lroth@burnsmc.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/acb8ed38-941a-4225-b4dc-43f0a635d10d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: 39th Annual J.P. Morgan Healthcare Conference Wednesday, January 13 at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference On-demand presentation available beginning Monday, January 11 at\u00a06:00 a.m.\u00a0Eastern Time Clinical Trial Panel Discussion at the H.C. Wainwright Virtual BioConnect ConferenceMonday, January 11 at\u00a012:00 p.m.\u00a0Eastern Time Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company&#8217;s website at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ChemoCentryx to Participate in Two Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-409459","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ChemoCentryx to Participate in Two Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ChemoCentryx to Participate in Two Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: 39th Annual J.P. Morgan Healthcare Conference Wednesday, January 13 at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference On-demand presentation available beginning Monday, January 11 at\u00a06:00 a.m.\u00a0Eastern Time Clinical Trial Panel Discussion at the H.C. Wainwright Virtual BioConnect ConferenceMonday, January 11 at\u00a012:00 p.m.\u00a0Eastern Time Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company&#8217;s website at &hellip; Continue reading &quot;ChemoCentryx to Participate in Two Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-06T13:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ChemoCentryx to Participate in Two Upcoming Investor Conferences\",\"datePublished\":\"2021-01-06T13:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/\"},\"wordCount\":306,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/\",\"name\":\"ChemoCentryx to Participate in Two Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=\",\"datePublished\":\"2021-01-06T13:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ChemoCentryx to Participate in Two Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ChemoCentryx to Participate in Two Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"ChemoCentryx to Participate in Two Upcoming Investor Conferences - Market Newsdesk","og_description":"MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) &#8212; ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.: 39th Annual J.P. Morgan Healthcare Conference Wednesday, January 13 at 11:40 a.m. Eastern Time H.C. Wainwright Virtual BioConnect Conference On-demand presentation available beginning Monday, January 11 at\u00a06:00 a.m.\u00a0Eastern Time Clinical Trial Panel Discussion at the H.C. Wainwright Virtual BioConnect ConferenceMonday, January 11 at\u00a012:00 p.m.\u00a0Eastern Time Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company&#8217;s website at &hellip; Continue reading \"ChemoCentryx to Participate in Two Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-06T13:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ChemoCentryx to Participate in Two Upcoming Investor Conferences","datePublished":"2021-01-06T13:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/"},"wordCount":306,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/","name":"ChemoCentryx to Participate in Two Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=","datePublished":"2021-01-06T13:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTI1OSMzOTA2MDE2IzIwMDY0MDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemocentryx-to-participate-in-two-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ChemoCentryx to Participate in Two Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=409459"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/409459\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=409459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=409459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=409459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}